Company Profile (AI Text)
Name: Axiom Biosciences
Canonical URL: https://wefunder.com/axiombiosciences
Updated at: 2026-11-02T04:36:03Z

Tagline: Precision regenerative therapies for brain injury. IPO ahead

Key claims:
- Total raised on Wefunder: 673616 | citation: https://wefunder.com/axiombiosciences#claim-total-raised
- Total investors: 58 | citation: https://wefunder.com/axiombiosciences#claim-total-investors

Verified facts:
- Total raised on Wefunder: 673616 | observed_at: 2026-11-02T04:36:03Z | expires_at: 2026-11-03T04:36:03Z
- Total investors: 58 | observed_at: 2026-11-02T04:36:03Z | expires_at: 2026-11-03T04:36:03Z

Computed metrics:
- total_amount_raised: 673616
- total_investors: 58
- team_size: 5
- featured_investor_count: 5
- faq_count: 1
- recent_post_count: 5

Quick facts:
- First US biotech targeting Hong Kong listing at $1B+ (2027); Nasdaq at $3B+ (2029); not guaranteed | citation: https://wefunder.com/axiombiosciences#claim-fact-1
- In clinical trial for IVH (brain bleeds in newborns): mortality eliminated, from ~46% to 0% | citation: https://wefunder.com/axiombiosciences#claim-fact-2
- $21M raised from VCs like Partners Investment & Proxima Ventures & 8 grants (NIH, CIRM, DoD) | citation: https://wefunder.com/axiombiosciences#claim-fact-3
- Targeting a $16.6B annual market in the US with 7+ years of FDA market exclusivity | citation: https://wefunder.com/axiombiosciences#claim-fact-4
- 50+ patents pending and 9 issued globally | citation: https://wefunder.com/axiombiosciences#claim-fact-5
- 2 FDA Rare Pediatric Disease Designations & potential Priority Review Vouchers; est. $400M+ value | citation: https://wefunder.com/axiombiosciences#claim-fact-6
- 2 FDA Orphan Disease Designations secure 7+ years of exclusivity, protecting $4.7B in revenue | citation: https://wefunder.com/axiombiosciences#claim-fact-7
- World-class team from Stanford, Cornell, Yale, NYU & Michigan, backed by J&J Innovation Labs | citation: https://wefunder.com/axiombiosciences#claim-fact-8

FAQ:
- Q: Could you share a bit more about the following? current valuation what I’d actually be investing in (share class) The expected dilution What you see as the key risks to the business over the next couple of years. Also… why HK?
  A: Hi Meghan, Thanks for the great questions. Axiom's current pre-money valuation is $80M. This isn't a conventional opportunity investment, we're extending part of our pre-IPO (aka Crossover) Round to retail investors. Technically you'd be investing in our Series A-2, but since this is our Crossover round (the final private raise before IPO), we don't expect to raise again before then, so no anticipated dilution. Key risk factors are in the attached document, please review them. On why HKEX: a ...

Recent posts:
- AI and drug development: Axiom live on CNBC! 🎥 (2026-09-04T15:07:53Z) https://wefunder.com/feed/378840
- A million-dollar biotech deal just validated something we're sitting on 🧬 (2026-08-29T13:13:43Z) https://wefunder.com/feed/376395
- 📣​Breaking News: We're setting our sights on a Hong Kong IPO (2026-07-22T22:06:58Z) https://wefunder.com/feed/355527
- We are onto something big here! (2026-07-21T23:43:12Z) https://wefunder.com/feed/356317
- Phase 1 Clinical Trial Results! (2026-07-14T12:58:23Z) https://wefunder.com/feed/352404